EEG / EMG in Minnesota

PMT Corporation, founded in 1979 and based in Chanhassen, Minnesota, is a manufacturer and distributor of specialty medical products and devices. The company focuses on research and development across neurosurgery, plastic and reconstructive surgery, orthopedic medicine, and gastrointestinal endoscopy. PMT's comprehensive product portfolio includes cortical surface electrodes for epilepsy monitoring, neuronavigation depth electrodes (AccuNav®), cervical traction halo fixation systems, tissue and breast expanders for reconstructive surgery, orthopedic collars and lumbo-sacral orthoses, and micropigmentation and dermabrasion devices. The company also manufactures the ALLURA® vaginal stent and Endomark™ gastric ink markers. Supported by a nationwide US and Canadian sales force and global distributor network, PMT provides 24/7 customer support and delivers sterile surgical supplies and specialized instruments to hospitals, surgical centers, and specialty practitioners.

EarliPoint Health is a healthcare technology company specializing in FDA-cleared eye-tracking diagnostic systems for early autism spectrum disorder (ASD) detection and assessment in children ages 16 months through 95 months (7–8 years). The EarliPoint System is a portable, tablet-based device that measures visual attention biomarkers through proprietary algorithms to provide objective, quantifiable data supporting qualified clinicians in ASD diagnosis and treatment progress monitoring. The system captures eye-gaze patterns while children watch video scenes featuring social interactions, analyzing three clinically aligned indices: language, cognition, and social engagement. The company's technology is grounded in decades of developmental research, with clinical validation from large-scale, double-blind studies published in the Journal of the American Medical Association (JAMA) in collaboration with Yale University and Emory University. FDA clearance was obtained via 510(k) submission, confirming substantial equivalence and safety standards. EarliPoint Health addresses critical gaps in early autism diagnosis—the average age of diagnosis in the U.S. exceeds 4 years, well past optimal intervention windows. The system is designed for clinical use in pediatric practices, behavioral health centers, child neurology clinics, and primary care facilities. Administration requires trained staff; interpretation requires qualified clinicians. Results are delivered same-day as detailed diagnostic or progress-tracking reports. The company operates an EarliPoint Network of partner clinics and research institutions including Drexel University Autism Institute, Cincinnati Children's Hospital, University of Nebraska Medical Center, and Easterseals Florida, expanding access across rural and underserved communities.

MGC Diagnostics Corporation is a global medical technology company specializing in non-invasive cardiorespiratory diagnostic products and systems. Founded in 1986 and headquartered in Saint Paul, Minnesota, the company designs and manufactures advanced diagnostic equipment for measuring respiratory function, gas exchange, and cardiovascular performance. Key product lines include pulmonary function testing systems, cardiopulmonary exercise testing (CPET/CPX) equipment, FeNO (fractional exhaled nitric oxide) monitoring systems, indirect calorimetry devices, stress testing systems, and treadmills. The company serves hospitals, clinics, sports medicine facilities, and pulmonary rehabilitation centers with integrated solutions for disease detection, chronic disease monitoring, and patient wellness across cardiorespiratory health. MGC Diagnostics provides comprehensive support including technical assistance, training programs, clinical research solutions, and preventive maintenance services.

NeuroOne Medical Technologies develops minimally invasive diagnostic and therapeutic neurosurgical devices based on proprietary thin-film electrode technology. The company's primary platform enables high-definition neuronal recording and ablation for functional neurosurgery, with an initial focus on epilepsy and trigeminal neuralgia treatment. Core products include the OneRF® Radiofrequency Ablation System (FDA-cleared K231675 for functional neurosurgical procedures; K251243 for trigeminal nerve ablation), which uniquely performs both diagnostic mapping and therapeutic ablation using the same stereotactic electroencephalography (sEEG) electrode. The Evo® sEEG System (FDA-cleared K222404) provides temporary subsurface brain recording, monitoring, and stimulation, while the Evo® Cortical Electrodes (FDA-cleared K192764) offer surface brain recording with reduced immunological response and improved cable management. NeuroOne's flexible thin-film electrode platform is designed to provide higher-resolution neural signal acquisition compared to conventional rigid electrodes, potentially reducing infection risk and procedure complexity. The company is developing a comprehensive portfolio for neurological applications beyond epilepsy, working with leading neurosurgical centers including Mayo Clinic. All devices are subject to federal restriction to sale by or on the order of a physician.